Tigilanol tiglate

DB18800InvestigationalSmall molecule

Tigilanol tiglate: Overview.

Mechanism: Pharmacologically active on Protein kinase C beta type, Protein kinase C alpha type, and Protein kinase C
Curator reviewed
Formula / weight: C₃₀H₄₂O₁₀ · 562.656 g/mol (avg)
Code names: EBC-46 · EBI-46

Resolves to

Compound

Clinical / RWD

Structure

[H][C@@]12C=C(C)C(=O)[C@@]1(O)[C@H](O)[C@@]1(CO)O[C@H]1[C@@]1([H])[C@@H]3C(C)(C)[C@]3(OC(=O)[C@@H](C)CC)[C@H](OC(=O)C(\C)=C\C)[C@@H](C)[C@]21O

Targets

What you can answer from here — as of July 09, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tigilanol tiglate, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.